Insmed Stock: A Blockbuster Launch, Priced Ahead Of Its Own Guidance (NASDAQ:INSM)
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
Insmed stock is rated Hold as BRINSUPRI launch optimism lifts shares. Read here for a detailed investment analysis of INSM stock.
Directly affected
- INSM Insmed+3.4% 17d
Named in this report.
Indirectly affected
- DIA SPDR Dow Jones Industrial Average ETF-0.8% 18d
SPDR Dow Jones Industrial Average ETF: it is a broad US stock-market fund. Linked by “nasdaq” (the broad US market) in this story.
- QQQ Invesco QQQ-9.8% 30d
Invesco QQQ: it is a broad US stock-market fund. Linked by “nasdaq” (the broad US market) in this story.
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Insmed belongs to, so it often moves with news about it.
- LLY Eli Lilly and+15.5% 30d
Eli Lilly and is a peer of Insmed in pharmaceutical preparations; rivals often move on the same news.
- JNJ Johnson & Johnson+0.1% 30d
Johnson & Johnson is a peer of Insmed in pharmaceutical preparations; rivals often move on the same news.
- ABBV AbbVie+9.0% 30d
AbbVie is a peer of Insmed in pharmaceutical preparations; rivals often move on the same news.
- MRK Merck+3.5% 30d
Merck is a peer of Insmed in pharmaceutical preparations; rivals often move on the same news.
- ABT Abbott Laboratories+10.3% 30d
Abbott Laboratories is a peer of Insmed in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| INSM | -4.47% | -3.92% | base | after close | after close | after close | after close |
| DIA | +1.38% | +4.07% | base | after close | after close | after close | after close |
| QQQ | +3.80% | +5.39% | base | after close | after close | after close | after close |
| XLV | -0.10% | +2.63% | base | after close | after close | after close | after close |
| LLY | +4.21% | +4.67% | base | after close | after close | after close | after close |
| JNJ | -2.08% | +0.00% | base | after close | after close | after close | after close |
| ABBV | -0.93% | +1.16% | base | after close | after close | after close | after close |
| MRK | +1.15% | +2.46% | base | after close | after close | after close | after close |
| ABT | +0.28% | +5.08% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Insmed Stock: A Blockbuster Launch, Priced Ahead Of Its Own Guidance (NASDAQ:INSM) Seeking Alpha
Source: Seeking Alpha
This story
| Company | When | Move | Status |
|---|---|---|---|
| ABBV | three days earlier | +1.16% | final price |
| ABBV | five days earlier | -0.93% | final price |
| ABT | three days earlier | +5.08% | final price |
| ABT | five days earlier | +0.28% | final price |
| DIA | three days earlier | +4.07% | final price |
| DIA | five days earlier | +1.38% | final price |
| INSM | three days earlier | -3.92% | final price |
| INSM | five days earlier | -4.47% | final price |
| JNJ | three days earlier | 0.00% | final price |
| JNJ | five days earlier | -2.08% | final price |
| LLY | three days earlier | +4.67% | final price |
| LLY | five days earlier | +4.21% | final price |
| MRK | three days earlier | +2.46% | final price |
| MRK | five days earlier | +1.15% | final price |
| QQQ | three days earlier | +5.39% | final price |
| QQQ | five days earlier | +3.80% | final price |
| XLV | three days earlier | +2.63% | final price |
| XLV | five days earlier | -0.10% | final price |
Congressional trades in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 64 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 38 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 43 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 60 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Pete Sessions sold AbbVie (ABBV), worth $15,001 - $50,000 on 14 Sep 2026. That is 54 days before publication. Filed 18 Sep 2026. View the filing.
- Rep. Rohit Khanna sold AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 64 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 44 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 80 days before publication. Filed 9 Sep 2026. View the filing.
- Rep. Pete Sessions sold Abbott Laboratories (ABT) (held by a spouse), worth $50,001 - $100,000 on 2 Oct 2026. That is 36 days before publication. Filed 27 Oct 2026. View the filing.
- Rep. Gilbert Cisneros bought Abbott Laboratories (ABT), worth $1,001 - $15,000 on 18 Sep 2026. That is 50 days before publication. Filed 12 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Abbott Laboratories (ABT), worth $1,001 - $15,000 on 17 Sep 2026. That is 51 days before publication. Filed 30 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
This story
12 out of 100
“Insmed Stock: A Blockbuster Launch, Priced Ahead Of Its Own Guidance (NASDAQ:INSM)” scores 12 out of 100. The score uses 1 sources.